Among these are the CD19-targeting CAR constructs approved for the treatment of B cell lymphoma: axicabtagene ciloleucel (Axi-cel) [8], tisagenleucel (Tisa-cel) [10,75,76], and lisocabtagene maraleucel (Liso-cel) [77]—the first of these with CD28 co-stimulation; the latter two with 41BB co-stimulation. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.